Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China

Injectable Antiretroviral Drugs: Back to the Future

(2021) Marco Berruti et al.   Viruses-Basel

Human immunodeficiency virus prevention strategies in China

(2020) Zun-You Wu et al.   CHINESE MEDICAL JOURNAL

Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery

(2020) Jing Yang et al.   WORLD JOURNAL OF SURGERY

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association between Sexual Habits and Sexually Transmitted Infections at a Specialised Centre in Granada (Spain)

(2020) Raquel Casado Santa-Bárbara et al.   International Journal of Environmental Research and Public Health

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

(2020) Bin Su et al.   CHINESE MEDICAL JOURNAL

Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004–2016

(2019) Yong-chao Qiao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

HIV estimates through 2018

(2019) Mary Mahy et al.   AIDS

Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens

(2017) Kenneth H. Mayer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

(2017) A Inciarte et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

(2017) Ana Milinkovic et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis

(2016) Nadia Valin et al.   BMC INFECTIOUS DISEASES

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges

(2016) Martina Kovarova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

(2016) Hongwei Zhang et al.   AIDS Research and Therapy

Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV

(2012) Kenneth H. Mayer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor

(2012) Huihui Chong et al.   PLoS One

An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life

(2009) D. Xie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY